{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"100"},{"groupId":"OG004","value":"100"},{"groupId":"OG005","value":"100"},{"groupId":"OG006","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"41"},{"groupId":"OG005","value":"50"},{"groupId":"OG006","value":"40"}],"units":"Participants"}],"description":"An adverse event was defined as any untoward medical occurrence in a clinical trial participants. The event did not necessarily have a relationship with study treatment. Adverse events included worsening of a pre-existing medical condition. Worsening indicated that the pre-existing medical condition had increased in severity, frequency, and/or duration or had an association with a worse outcome. A pre-existing condition that had not worsened during the study or involved an intervention such as elective cosmetic surgery or a medical procedure while on study, was not considered an adverse event. TEAE was defined as any AE with onset on or after the start of treatment.","groups":[{"description":"Participants with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL) received conditioning chemotherapy (fludarabine 30 mg/m\\^2 intravenously \\[IV\\] over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel chimeric antigen receptor (CAR) transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of body weight (BW) on Day 0.","id":"OG000","title":"Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy"},{"description":"Participants with refractory DLBCL received conditioning chemotherapy (fludarabine 30 mg/m\\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0.","id":"OG001","title":"Phase 2 (Pivotal Study): Cohort 1"},{"description":"Participants with refractory PMBCL or TFL received conditioning chemotherapy (fludarabine 30 mg/m\\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0.","id":"OG002","title":"Phase 2 (Pivotal Study): Cohort 2"},{"description":"Participants with relapsed or refractory transplant ineligible DLBCL, PMBCL, or TFL received conditioning chemotherapy (fludarabine 30 mg/m\\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0. Participants also received a prophylactic regimen of levetiracetam (750 mg orally or IV twice daily (BID) starting on Day 0) and tocilizumab (8 mg/kg IV over 1 hour (not to exceed 800 mg)) on Day 2).","id":"OG003","title":"Phase 2 (Safety Management Study): Cohort 3"},{"description":"Participants with r/r DLBCL, PMBCL ,TFL, or high-grade B-cell lymphoma (HGBCL) after 2 systemic lines of therapy received optional bridging therapy (dexamethasone 20mg to 40mg,either orally or IV daily for 1 to 4 days or 1g/m\\^2 of high-dose methylprednisolone(HDMP) for 3 days with rituximab at 375mg/m\\^2 weekly for 3 weeks or bendamustine 90 mg/m\\^2 on Days 1 and 2 and rituximab 375mg/m\\^2 on Day 1), conditioning chemotherapy (fludarabine 30mg/m\\^2 IV and cyclophosphamide 500mg/m\\^2 IV)on Days -5,-4, and -3; followed by single infusion of axicabtagene ciloleucel CAR transduced autologous T cells IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW. Participants also received a prophylactic regimen of levetiracetam (750 mg orally or IV twice daily (BID) starting on Day 0). Participants received tocilizumab (initiated on persistent Grade 1 CRS for over 24 hours) and dexamethasone (persistent Grade 1 CRS for over 72 hours and at onset of Grade 1 neurologic toxicity).","id":"OG004","title":"Phase 2 (Safety Management Study): Cohort 4"},{"description":"Participants with r/r DLBCL, PMBCL ,TFL, or HGBCL after 2 systemic lines of therapy received debulking therapy (R-CHOP:rituximab 375mg/m\\^2 D1,doxorubicin 50mg/m\\^2 D1,prednisone 100mg D1 to D5,cyclophosphamide 750mg/m\\^2 D1,vincristine 1.4 mg/m\\^2 D1 or R-ICE:rituximab 375mg/ m\\^2 D1,ifosfamide 5g/m\\^2 24h-CI D2,carboplatin AUC5 D2 maximum dose 800mg,etoposide 100 mg/m\\^2/day D1 to D3 or R-GEMOX:rituximab 375mg/m\\^2 D1,gemcitabine 1000mg/m\\^2 D2,oxaliplatin 100mg/m\\^2 D2 or R-GDP:rituximab 375mg/m\\^2 D1 or D8,gemcitabine 1g/m\\^2 D1 \\& D8,dexamethasone 40mg D1 to D4,cisplatin 75mg/m\\^2 D1(or carboplatin AUC5 D1) or radiotherapy:20 to 30 Gy), conditioning chemotherapy (fludarabine 30mg/m\\^2 IV and cyclophosphamide 500mg/m\\^2 IV)on Days -5,-4, and -3; followed by single infusion of axicabtagene ciloleucel at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0. Participants also received a prophylactic regimen of levetiracetam (750 mg orally or IV BID starting on D0).D=Day.","id":"OG005","title":"Phase 2 (Safety Management Study): Cohort 5"},{"description":"Participants with r/r DLBCL, PMBCL ,TFL, or HGBCL after 2 systemic lines of therapy may have received bridging therapy (dexamethasone 20mg to 40mg, either orally or IV daily for 1 to 4 days or 1g/m\\^2 of high-dose methylprednisolone(HDMP) for 3 days with rituximab at 375mg/m\\^2 weekly for 3 weeks or bendamustine 90 mg/m\\^2 on Days 1 and 2 and rituximab 375mg/m\\^2 on Day 1), conditioning chemotherapy (fludarabine 30mg/m\\^2 IV and cyclophosphamide 500mg/m\\^2 IV)on Days -5,-4, and -3; followed by single infusion of axicabtagene ciloleucel CAR transduced autologous T cells IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0. Participants also received a prophylactic regimen of levetiracetam (750 mg orally or IV twice daily (BID) starting on Day 0) and corticosteroids (dexamethasone, 10 mg once daily on Days 0, 1, and 2). Participants received tocilizumab (initiated on persistent Grade 1 CRS for over 24 hours) and dexamethasone (persistent Grade 1 CRS for over 72 hours and at onset of Grade 1 neurologic toxicity).","id":"OG006","title":"Phase 2 (Safety Management Study): Cohort 6"}],"paramType":"NUMBER","populationDescription":"Participants in the Safety Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"First infusion date of axicabtagene ciloleucel up to last follow up visit (maximum duration: 7.7 years)","title":"Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}